Getting a new hip or knee replacement is a big deal. You want that surgery to heal well without complications. But infections can happen. They are hard to treat and can ruin the new joint. A new look at many studies helps clarify which antibiotics work best to stop these infections before they start. This analysis checked data from more than 200,000 surgeries. It compared two groups of patients. One group got cephalosporins like cefazolin or cefuroxime. The other group got different antibiotics that are not cephalosporins. Both groups were adults having their first joint replacement. The goal was simple: keep the infection rate low. The results were clear for the main worry. Patients who received cephalosporins had lower odds of getting a prosthetic joint infection. The numbers showed a meaningful drop in risk compared to the other drugs. There was no big difference found for surgical site infections overall. This means the main benefit was protecting the implant itself. The evidence is graded as moderate. This means the findings are solid but not perfect. Some of the original studies varied in how they were done. This variation makes the overall picture a bit less sharp. Still, the message stands. Cephalosporins remain the preferred choice for preventing infection in these surgeries. They offer a safer path for patients hoping for a smooth recovery.
Meta-analysis shows lower prosthetic joint infection odds with cephalosporins versus non-cephalosporin prophylaxis in primary arthroplastyCephalosporins lower prosthetic joint infection risk in primary hip and knee replacements
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This systematic review and meta-analysis examined the efficacy of single-agent cephalosporin prophylaxis compared to single-agent non-cephalosporin antibiotics in adults undergoing primary arthroplasty. The analysis included a substantial number of procedures across the cephalosporin and non-cephalosporin arms. The primary outcome focused on prosthetic joint infection, while surgical site infection served as a secondary outcome.
The results indicated that the odds of prosthetic joint infection were lower with cephalosporins. In contrast, no overall difference was observed regarding surgical site infection between the two antibiotic classes. The authors noted that randomized trial estimates were limited and heterogeneous, which prevented the findings from reaching statistical significance in certain contexts.
The authors highlighted that evidence comparing outcomes across antibiotic classes remains variable. They graded the certainty of the evidence as moderate and explicitly advised against inferring causation from the observed associations. Consequently, cephalosporins, particularly cefazolin or cefuroxime, remain the preferred prophylactic agents for primary arthroplasty based on current practice relevance.